Phase III Study Comparing Shorter 2- and 4-Week Benznidazole Treatments to the Standard 8-Week Regimen for Adults With Chronic Chagas Disease
Led by Laboratorio Elea Phoenix S.A. · Updated on 2023-11-30
300
Participants Needed
6
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Chagas disease is a parasitic infection caused by Trypanosoma cruzi, affecting millions worldwide, especially in Latin America. Current treatments with benznidazole and nifurtimox have significant side effects and long durations, making it difficult for many adults to complete therapy. This study evaluates whether shorter treatment plans of 14 and 28 days with benznidazole are as effective as the standard 60-day course, aiming to improve safety and treatment completion rates in adults with chronic Chagas disease in its indeterminate or mild cardiac forms.
Participants will be randomly assigned to one of three groups receiving benznidazole at 300 mg daily divided into three doses a 2-week regimen, a 4-week regimen, or the standard 8-week regimen. The study is a Phase III, multicenter, randomized trial comparing the efficacy and safety of these three treatment durations. The two shorter regimens are experimental, while the 8-week treatment serves as the active comparator.
During the study, participants will have periodic blood tests using qualitative PCR to monitor parasite levels from the end of treatment up to 12 months afterward. Safety will be assessed by tracking adverse events and treatment interruptions. Researchers will also observe patient adherence to treatment in each group. Overall participation includes treatment and follow-up visits over at least 12 months to evaluate sustained parasite clearance and safety outcomes.
CONDITIONS
Brief Title
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Research Team
C
Carola Lombas, MD
T
Tayná Marques, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of Trypanosoma cruzi infection by at least two reactive serology tests
Positive qualitative PCR test for T. cruzi
For women of childbearing potential: negative pregnancy test, not breastfeeding, and use of effective contraception during treatment and 30 days after
Ability to comply with study exams and visits
Having a permanent address
Heart rate between 50-100 bpm or isolated sinus bradycardia (41-59 bpm); QRS ≤120 msec; QTc 350-450 msec, or non-severe chagasic cardiomyopathy findings
Normal or minimal changes on echocardiogram without severe cardiac dysfunction
No signs or symptoms of moderate to severe chronic cardiac or digestive Chagas disease
No prior mental disorders or suicidal tendencies
No acute or chronic illnesses interfering with study evaluation
No contraindication to benznidazole
No history of allergy or serious reactions to nitroimidazole compounds
No prior antiparasitic treatment for T. cruzi
No history of drug abuse or alcoholism
Able to take oral medication
You will not qualify if you...
Pregnant or intending to become pregnant during or within 30 days after treatment
Signs or symptoms of moderate to severe chronic cardiac or digestive Chagas disease
ECG or echocardiographic abnormalities not allowed by inclusion criteria
History of cardiomyopathy, heart failure, or severe ventricular arrhythmia
History of digestive surgery related to Chagas disease or megacolon/mega-esophagus
Acute or chronic diseases interfering with safety or efficacy evaluation
Abnormal lab test values beyond allowable limits
Conditions preventing oral medication intake
Known hypersensitivity to nitroimidazole compounds
History of allergy, asthma, intolerance, or photosensitivity
Use of interfering medications like allopurinol or antimicrobials
Scheduled surgery interfering with trial
Inability to attend visits or comply with study procedures
Prior participation in T. cruzi treatment trials
Participation in other trials within 3 months
Serious medical or psychiatric illness increasing risk or affecting results
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 2, 4, or 8 weeks depending on assigned treatment group
Participants receive benznidazole treatment in one of three regimens: 2 weeks, 4 weeks, or the standard 8 weeks, to reduce and eliminate the Trypanosoma cruzi parasite.
Visits occur during the treatment period as required for medication administration and monitoring
Follow-up
Duration - Up to 12 months after treatment
Participants are monitored for up to 12 months after treatment to assess parasite clearance, safety, and adherence to the treatment.
Visits at 1, 4, 6, 8 months and additional visits up to 12 months for safety and efficacy assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Randomized Controlled Study to Evaluate LXE408 for Chronic Chagas Disease Without Severe Organ Dysfunction Comparing Safety and Efficacy to Benznidazole and Placebo
Phase III Study Comparing Shorter 2- and 4-Week Benznidazole Treatments to the Standard 8-Week Regimen for Adults With Chronic Chagas Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial.